Emcure Pharmaceuticals Ltd: Q2FY27 results
Emcure Pharmaceuticals Ltd reported revenue of Rs 2,820 cr and net profit of Rs 325 cr for Q2FY27.
Filed 03 Nov 2026, 13:44 IST · Emcure Pharmaceuticals Ltd (EMCURE)
Price around the results
What was reported
Emcure Pharmaceuticals Ltd reported revenue of Rs 2,820 cr and net profit of Rs 325 cr for Q2FY27. Figures are consolidated.
How it compares
Revenue changed +24.26% from a year earlier. Against the previous quarter revenue changed +9.30%.
How the stock reacted
The stock closed +4.42% on the session after the results.
Q2FY27 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q2FY27 | Q1FY27 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹2,820 cr | ₹2,580 cr | +9.30% | +24.26% |
| Other income | ₹3 cr | ₹2 cr | +57.00% | +4.17% |
| Expenses | ₹2,233 cr | ₹2,048 cr | +9.02% | +24.43% |
| Operating profit | ₹588 cr | ₹533 cr | +10.39% | +23.63% |
| Operating margin (%) | 20.84% | 20.64% | — | — |
| Interest | ₹36 cr | ₹32 cr | +12.81% | +9.34% |
| Depreciation | ₹110 cr | ₹110 cr | +0.15% | +4.80% |
| Profit before tax | ₹446 cr | ₹394 cr | +13.30% | +30.59% |
| Tax | ₹121 cr | ₹101 cr | +19.55% | +34.13% |
| Net profit | ₹325 cr | ₹292 cr | +11.14% | +29.32% |
| EPS (₹) | ₹17.16 | ₹15.50 | +10.71% | +33.54% |
Operating margin of 20.84% compares with a Healthcare sector median of 21.24% across 56 peers that have reported Q2FY27.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | +4.42% | +2.84% |
Volume on the results session was 10.03× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- The company identifies three strategic priorities underpinning its FY26-FY30 growth aspiration.
- For FY27, the company plans to deepen its anaemia franchise and scale other women’s health areas.
- The near-term European pipeline has a total addressable market of USD 1 billion.
Expansion
- The Manx acquisition expanded the company’s European business.
- The company has a differentiated pipeline of complex injectables and biosimilars supported by in-licensing.
New products
- The company’s differentiated products pipeline includes lenacapavir, liposomal amphotericin B, tenecteplase, enoxaparin, FCM and bevacizumab.
New initiatives
- The company continued investing in newer technologies.
Competition
- The company has a market-leading position in key oncology, renal and transplant molecules.